Article
primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.
European journal of cancer (Oxford, England : 1990) - 9 Sept 2026
van Akkooi Alexander Cj, Kicinski Michal, Govaerts Anne-Sophie, Hauschild Axel, Rutkowski Piotr, Arenberger Petr, Ascierto Paolo A, Tomczak Piotr, Quereux Gaëlle, De Galitiis Federica, Dutriaux Caroline, Gebhardt Christoffer, Kapiteijn Ellen, Machet Laurent, Berciano Miguel Ga, Del Vecchio Michele, Jalving Mathilde, Jouary Thomas, Krajsova Ivana, Matkovic Suzana, Merelli Barbara, Mortier Laurent, Pagès-Laurent Pages-LaurentCecile, Palmieri Giuseppe, Pracht Marc, Vantuchova Yvetta, Massi Daniela, Elaut Nathalie, de Schaetzen Gaetan, Nuyens Sarah, Jha Nitish, Klauck Isabelle, Sansas Benoît, Vedovato Jean Claude, Lorigan Paul C, Long Georgina V, Eggermont Alexander Mm, Mandala Mario
Abstract excerpt
PURPOSE: Stage IIB/IIC melanoma has a high risk of recurrence after resection. Combined BRAF/MEK inhibitor therapy showed benefit in resected high-risk stage III and advanced melanoma. The objective of this study was to investigate its role in stage IIB/IIC. METHODS: Adult patients with resected stage IIB/IIC cutaneous melanoma which had a BRAF V600E/K mutation were randomized 1:1 to receive encorafenib (enco)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.